MDMB-BINACA

Synthetic cannabinoid

{{Drugbox | verifiedrevid = 477318752 | IUPAC_name = Methyl 2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate | image = MDMB-BINACA_structure.png | width = 200 | legal_status = Illegal in many jurisdictions | CAS_number = 1971007-92-7 | PubChem = 119025019 | ChemSpiderID = 52085148 | UNII = 7J1X0R8F8H | C=21 | H=29 | N=3 | O=3 | smiles = CC(C)(C)C(C(=O)OC)NC(=O)c1nn(CC2CCCCC2)c3ccccc13 }}

MDMB-BINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the cannabinoid receptors, which are part of the endocannabinoid system in the human body. This compound is often found in "spice" or "K2" products, which are marketed as legal alternatives to cannabis.

Chemical Structure and Properties

MDMB-BINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is methyl 2-[[1-(cyclohexylmethyl)-1H-indazole-3-carbonyl]amino]-3,3-dimethylbutanoate. The compound features a cyclohexylmethyl group attached to the indazole core, which is a common structural motif in many synthetic cannabinoids.

Pharmacology

MDMB-BINACA acts as a potent agonist at the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes including mood, memory, appetite, and pain sensation. The activation of these receptors by MDMB-BINACA can lead to psychoactive effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Effects and Toxicity

The effects of MDMB-BINACA can include euphoria, altered perception, and relaxation, but it can also cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, seizures or death. The toxicity of MDMB-BINACA is not well-documented, but synthetic cannabinoids are generally associated with a higher risk of severe adverse effects compared to natural cannabis.

Legal Status

MDMB-BINACA is illegal in many countries due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids as a class. In the United States, it is classified as a Schedule I controlled substance under the Controlled Substances Act.

Synthesis

The synthesis of MDMB-BINACA involves the reaction of a substituted indazole with a suitable acid chloride to form the amide linkage, followed by esterification. The specific synthetic routes can vary, and detailed procedures are typically found in chemical literature or patent filings.

Detection in Biological Samples

MDMB-BINACA can be detected in biological samples using techniques such as gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods are used in forensic and clinical toxicology to confirm exposure to the compound.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system
• Spice (drug)
• K2 (drug)